Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 44

1.

AllergoOncology: Expression platform development and functional profiling of an anti-HER2 IgE antibody.

Ilieva KM, Fazekas-Singer J, Bax HJ, Crescioli S, Montero-Morales L, Mele S, Sow HS, Stavraka C, Josephs DH, Spicer JF, Steinkellner H, Jensen-Jarolim E, Tutt ANJ, Karagiannis SN.

Allergy. 2019 Apr 9. doi: 10.1111/all.13818. [Epub ahead of print] No abstract available.

PMID:
30964550
2.

PARP inhibition enhances tumor cell-intrinsic immunity in ERCC1-deficient non-small cell lung cancer.

Chabanon RM, Muirhead G, Krastev DB, Adam J, Morel D, Garrido M, Lamb A, Hénon C, Dorvault N, Rouanne M, Marlow R, Bajrami I, Cardeñosa ML, Konde A, Besse B, Ashworth A, Pettitt SJ, Haider S, Marabelle A, Tutt AN, Soria JC, Lord CJ, Postel-Vinay S.

J Clin Invest. 2019 Mar 1;129(3):1211-1228. doi: 10.1172/JCI123319. Epub 2019 Feb 11.

3.

A Four-gene Decision Tree Signature Classification of Triple-negative Breast Cancer: Implications for Targeted Therapeutics.

Quist J, Mirza H, Cheang MCU, Telli ML, O'Shaughnessy JA, Lord CJ, Tutt ANJ, Grigoriadis A.

Mol Cancer Ther. 2019 Jan;18(1):204-212. doi: 10.1158/1535-7163.MCT-18-0243. Epub 2018 Oct 10.

4.

Anti-Folate Receptor Alpha-Directed Antibody Therapies Restrict the Growth of Triple-negative Breast Cancer.

Cheung A, Opzoomer J, Ilieva KM, Gazinska P, Hoffmann RM, Mirza H, Marlow R, Francesch-Domenech E, Fittall M, Dominguez Rodriguez D, Clifford A, Badder L, Patel N, Mele S, Pellizzari G, Bax HJ, Crescioli S, Petranyi G, Larcombe-Young D, Josephs DH, Canevari S, Figini M, Pinder S, Nestle FO, Gillett C, Spicer JF, Grigoriadis A, Tutt ANJ, Karagiannis SN.

Clin Cancer Res. 2018 Oct 15;24(20):5098-5111. doi: 10.1158/1078-0432.CCR-18-0652. Epub 2018 Aug 1.

5.

Evaluation of Antigen-Conjugated Fluorescent Beads to Identify Antigen-Specific B Cells.

Correa I, Ilieva KM, Crescioli S, Lombardi S, Figini M, Cheung A, Spicer JF, Tutt ANJ, Nestle FO, Karagiannis P, Lacy KE, Karagiannis SN.

Front Immunol. 2018 Mar 23;9:493. doi: 10.3389/fimmu.2018.00493. eCollection 2018.

6.

E-Cadherin/ROS1 Inhibitor Synthetic Lethality in Breast Cancer.

Bajrami I, Marlow R, van de Ven M, Brough R, Pemberton HN, Frankum J, Song F, Rafiq R, Konde A, Krastev DB, Menon M, Campbell J, Gulati A, Kumar R, Pettitt SJ, Gurden MD, Cardenosa ML, Chong I, Gazinska P, Wallberg F, Sawyer EJ, Martin LA, Dowsett M, Linardopoulos S, Natrajan R, Ryan CJ, Derksen PWB, Jonkers J, Tutt ANJ, Ashworth A, Lord CJ.

Cancer Discov. 2018 Apr;8(4):498-515. doi: 10.1158/2159-8290.CD-17-0603.

7.

Integrated genomics and functional validation identifies malignant cell specific dependencies in triple negative breast cancer.

Patel N, Weekes D, Drosopoulos K, Gazinska P, Noel E, Rashid M, Mirza H, Quist J, Brasó-Maristany F, Mathew S, Ferro R, Pereira AM, Prince C, Noor F, Francesch-Domenech E, Marlow R, de Rinaldis E, Grigoriadis A, Linardopoulos S, Marra P, Tutt ANJ.

Nat Commun. 2018 Mar 13;9(1):1044. doi: 10.1038/s41467-018-03283-z.

8.

Driver Oncogenes but Not as We Know Them: Targetable Fusion Genes in Breast Cancer.

Natrajan R, Tutt ANJ, Lord CJ.

Cancer Discov. 2018 Mar;8(3):272-275. doi: 10.1158/2159-8290.CD-18-0091.

9.

Antibody structure and engineering considerations for the design and function of Antibody Drug Conjugates (ADCs).

Hoffmann RM, Coumbe BGT, Josephs DH, Mele S, Ilieva KM, Cheung A, Tutt AN, Spicer JF, Thurston DE, Crescioli S, Karagiannis SN.

Oncoimmunology. 2017 Nov 20;7(3):e1395127. doi: 10.1080/2162402X.2017.1395127. eCollection 2018.

10.

Chondroitin Sulfate Proteoglycan 4 and Its Potential As an Antibody Immunotherapy Target across Different Tumor Types.

Ilieva KM, Cheung A, Mele S, Chiaruttini G, Crescioli S, Griffin M, Nakamura M, Spicer JF, Tsoka S, Lacy KE, Tutt ANJ, Karagiannis SN.

Front Immunol. 2018 Jan 10;8:1911. doi: 10.3389/fimmu.2017.01911. eCollection 2017. Review.

11.

Engineering and stable production of recombinant IgE for cancer immunotherapy and AllergoOncology.

Crescioli S, Chiaruttini G, Mele S, Ilieva KM, Pellizzari G, Spencer DIR, Gardner RA, Lacy KE, Spicer JF, Tutt ANJ, Wagner GK, Karagiannis SN.

J Allergy Clin Immunol. 2018 Apr;141(4):1519-1523.e9. doi: 10.1016/j.jaci.2017.12.986. Epub 2018 Jan 31. No abstract available.

12.

Functionally Active Fc Mutant Antibodies Recognizing Cancer Antigens Generated Rapidly at High Yields.

Ilieva KM, Fazekas-Singer J, Achkova DY, Dodev TS, Mele S, Crescioli S, Bax HJ, Cheung A, Karagiannis P, Correa I, Figini M, Marlow R, Josephs DH, Beavil AJ, Maher J, Spicer JF, Jensen-Jarolim E, Tutt AN, Karagiannis SN.

Front Immunol. 2017 Sep 11;8:1112. doi: 10.3389/fimmu.2017.01112. eCollection 2017.

13.

Targeting TAO Kinases Using a New Inhibitor Compound Delays Mitosis and Induces Mitotic Cell Death in Centrosome Amplified Breast Cancer Cells.

Koo CY, Giacomini C, Reyes-Corral M, Olmos Y, Tavares IA, Marson CM, Linardopoulos S, Tutt AN, Morris JDH.

Mol Cancer Ther. 2017 Nov;16(11):2410-2421. doi: 10.1158/1535-7163.MCT-17-0077. Epub 2017 Aug 22.

14.

Erratum: PIM1 kinase regulates cell death, tumor growth and chemotherapy response in triple-negative breast cancer.

Brasó-Maristany F, Filosto S, Catchpole S, Marlow R, Quist J, Francesch-Domenech E, Plumb DA, Zakka L, Gazinska P, Liccardi G, Meier P, Gris-Oliver A, Cheang MCU, Perdrix-Rosell A, Shafat M, Noël E, Patel N, McEachern K, Scaltriti M, Castel P, Noor F, Buus R, Mathew S, Watkins J, Serra V, Marra P, Grigoriadis A, Tutt AN.

Nat Med. 2017 Jun 6;23(6):788. doi: 10.1038/nm0617-788b. No abstract available.

PMID:
28586336
15.

Erratum: PIM1 kinase regulates cell death, tumor growth and chemotherapy response in triple-negative breast cancer.

Brasó-Maristany F, Filosto S, Catchpole S, Marlow R, Quist J, Francesch-Domenech E, Plumb DA, Zakka L, Gazinska P, Liccardi G, Meier P, Gris-Oliver A, Cheang MC, Perdrix-Rosell A, Shafat M, Noël E, Patel N, McEachern K, Scaltriti M, Castel P, Noor F, Buus R, Mathew S, Watkins J, Serra V, Marra P, Grigoriadis A, Tutt AN.

Nat Med. 2017 Apr 7;23(4):526. doi: 10.1038/nm0417-526c. No abstract available.

PMID:
28388604
16.

RORγt+ Innate Lymphoid Cells Promote Lymph Node Metastasis of Breast Cancers.

Irshad S, Flores-Borja F, Lawler K, Monypenny J, Evans R, Male V, Gordon P, Cheung A, Gazinska P, Noor F, Wong F, Grigoriadis A, Fruhwirth GO, Barber PR, Woodman N, Patel D, Rodriguez-Justo M, Owen J, Martin SG, Pinder SE, Gillett CE, Poland SP, Ameer-Beg S, McCaughan F, Carlin LM, Hasan U, Withers DR, Lane P, Vojnovic B, Quezada SA, Ellis P, Tutt AN, Ng T.

Cancer Res. 2017 Mar 1;77(5):1083-1096. doi: 10.1158/0008-5472.CAN-16-0598. Epub 2017 Jan 12.

17.

Functional and prognostic significance of the genomic amplification of frizzled 6 (FZD6) in breast cancer.

Corda G, Sala G, Lattanzio R, Iezzi M, Sallese M, Fragassi G, Lamolinara A, Mirza H, Barcaroli D, Ermler S, Silva E, Yasaei H, Newbold RF, Vagnarelli P, Mottolese M, Natali PG, Perracchio L, Quist J, Grigoriadis A, Marra P, Tutt AN, Piantelli M, Iacobelli S, De Laurenzi V, Sala A.

J Pathol. 2017 Feb;241(3):350-361. doi: 10.1002/path.4841. Epub 2016 Dec 29.

18.

PIM1 kinase regulates cell death, tumor growth and chemotherapy response in triple-negative breast cancer.

Brasó-Maristany F, Filosto S, Catchpole S, Marlow R, Quist J, Francesch-Domenech E, Plumb DA, Zakka L, Gazinska P, Liccardi G, Meier P, Gris-Oliver A, Cheang MC, Perdrix-Rosell A, Shafat M, Noël E, Patel N, McEachern K, Scaltriti M, Castel P, Noor F, Buus R, Mathew S, Watkins J, Serra V, Marra P, Grigoriadis A, Tutt AN.

Nat Med. 2016 Nov;22(11):1303-1313. doi: 10.1038/nm.4198. Epub 2016 Oct 24. Erratum in: Nat Med. 2017 Apr 7;23 (4):526. Nat Med. 2017 Jun 6;23 (6):788.

19.

Targeting folate receptor alpha for cancer treatment.

Cheung A, Bax HJ, Josephs DH, Ilieva KM, Pellizzari G, Opzoomer J, Bloomfield J, Fittall M, Grigoriadis A, Figini M, Canevari S, Spicer JF, Tutt AN, Karagiannis SN.

Oncotarget. 2016 Aug 9;7(32):52553-52574. doi: 10.18632/oncotarget.9651. Review.

20.

Mutation Processes in 293-Based Clones Overexpressing the DNA Cytosine Deaminase APOBEC3B.

Akre MK, Starrett GJ, Quist JS, Temiz NA, Carpenter MA, Tutt AN, Grigoriadis A, Harris RS.

PLoS One. 2016 May 10;11(5):e0155391. doi: 10.1371/journal.pone.0155391. eCollection 2016.

21.

Robust BRCA1-like classification of copy number profiles of samples repeated across different datasets and platforms.

Schouten PC, Grigoriadis A, Kuilman T, Mirza H, Watkins JA, Cooke SA, van Dyk E, Severson TM, Rueda OM, Hoogstraat M, Verhagen CV, Natrajan R, Chin SF, Lips EH, Kruizinga J, Velds A, Nieuwland M, Kerkhoven RM, Krijgsman O, Vens C, Peeper D, Nederlof PM, Caldas C, Tutt AN, Wessels LF, Linn SC.

Mol Oncol. 2015 Aug;9(7):1274-86. doi: 10.1016/j.molonc.2015.03.002. Epub 2015 Mar 20.

22.

Genomic Complexity Profiling Reveals That HORMAD1 Overexpression Contributes to Homologous Recombination Deficiency in Triple-Negative Breast Cancers.

Watkins J, Weekes D, Shah V, Gazinska P, Joshi S, Sidhu B, Gillett C, Pinder S, Vanoli F, Jasin M, Mayrhofer M, Isaksson A, Cheang MC, Mirza H, Frankum J, Lord CJ, Ashworth A, Vinayak S, Ford JM, Telli ML, Grigoriadis A, Tutt AN.

Cancer Discov. 2015 May;5(5):488-505. doi: 10.1158/2159-8290.CD-14-1092. Epub 2015 Mar 13.

23.

Synthetic lethality and cancer therapy: lessons learned from the development of PARP inhibitors.

Lord CJ, Tutt AN, Ashworth A.

Annu Rev Med. 2015;66:455-70. doi: 10.1146/annurev-med-050913-022545. Epub 2014 Oct 17. Review.

PMID:
25341009
24.

Genomic scars as biomarkers of homologous recombination deficiency and drug response in breast and ovarian cancers.

Watkins JA, Irshad S, Grigoriadis A, Tutt AN.

Breast Cancer Res. 2014 Jun 3;16(3):211. doi: 10.1186/bcr3670. Review.

25.

Critical research gaps and translational priorities for the successful prevention and treatment of breast cancer.

Eccles SA, Aboagye EO, Ali S, Anderson AS, Armes J, Berditchevski F, Blaydes JP, Brennan K, Brown NJ, Bryant HE, Bundred NJ, Burchell JM, Campbell AM, Carroll JS, Clarke RB, Coles CE, Cook GJ, Cox A, Curtin NJ, Dekker LV, Silva Idos S, Duffy SW, Easton DF, Eccles DM, Edwards DR, Edwards J, Evans D, Fenlon DF, Flanagan JM, Foster C, Gallagher WM, Garcia-Closas M, Gee JM, Gescher AJ, Goh V, Groves AM, Harvey AJ, Harvie M, Hennessy BT, Hiscox S, Holen I, Howell SJ, Howell A, Hubbard G, Hulbert-Williams N, Hunter MS, Jasani B, Jones LJ, Key TJ, Kirwan CC, Kong A, Kunkler IH, Langdon SP, Leach MO, Mann DJ, Marshall JF, Martin L, Martin SG, Macdougall JE, Miles DW, Miller WR, Morris JR, Moss SM, Mullan P, Natrajan R, O'Connor JP, O'Connor R, Palmieri C, Pharoah PD, Rakha EA, Reed E, Robinson SP, Sahai E, Saxton JM, Schmid P, Smalley MJ, Speirs V, Stein R, Stingl J, Streuli CH, Tutt AN, Velikova G, Walker RA, Watson CJ, Williams KJ, Young LS, Thompson AM.

Breast Cancer Res. 2013 Oct 1;15(5):R92. doi: 10.1186/bcr3493. Review.

26.

Signatures of mutational processes in human cancer.

Alexandrov LB, Nik-Zainal S, Wedge DC, Aparicio SA, Behjati S, Biankin AV, Bignell GR, Bolli N, Borg A, Børresen-Dale AL, Boyault S, Burkhardt B, Butler AP, Caldas C, Davies HR, Desmedt C, Eils R, Eyfjörd JE, Foekens JA, Greaves M, Hosoda F, Hutter B, Ilicic T, Imbeaud S, Imielinski M, Jäger N, Jones DT, Jones D, Knappskog S, Kool M, Lakhani SR, López-Otín C, Martin S, Munshi NC, Nakamura H, Northcott PA, Pajic M, Papaemmanuil E, Paradiso A, Pearson JV, Puente XS, Raine K, Ramakrishna M, Richardson AL, Richter J, Rosenstiel P, Schlesner M, Schumacher TN, Span PN, Teague JW, Totoki Y, Tutt AN, Valdés-Mas R, van Buuren MM, van 't Veer L, Vincent-Salomon A, Waddell N, Yates LR; Australian Pancreatic Cancer Genome Initiative; ICGC Breast Cancer Consortium; ICGC MMML-Seq Consortium; ICGC PedBrain, Zucman-Rossi J, Futreal PA, McDermott U, Lichter P, Meyerson M, Grimmond SM, Siebert R, Campo E, Shibata T, Pfister SM, Campbell PJ, Stratton MR.

Nature. 2013 Aug 22;500(7463):415-21. doi: 10.1038/nature12477. Epub 2013 Aug 14. Erratum in: Nature. 2013 Oct 10;502(7470):258. Imielinsk, Marcin [corrected to Imielinski, Marcin].

27.

Comparison of basal-like triple-negative breast cancer defined by morphology, immunohistochemistry and transcriptional profiles.

Gazinska P, Grigoriadis A, Brown JP, Millis RR, Mera A, Gillett CE, Holmberg LH, Tutt AN, Pinder SE.

Mod Pathol. 2013 Jul;26(7):955-66. doi: 10.1038/modpathol.2012.244. Epub 2013 Feb 8.

28.

Platinum chemotherapy for BRCA1-related breast cancer: do we need more evidence?

Turner NC, Tutt AN.

Breast Cancer Res. 2012 Nov 13;14(6):115. doi: 10.1186/bcr3332.

29.

Biologic markers determine both the risk and the timing of recurrence in breast cancer.

Esserman LJ, Moore DH, Tsing PJ, Chu PW, Yau C, Ozanne E, Chung RE, Tandon VJ, Park JW, Baehner FL, Kreps S, Tutt AN, Gillett CE, Benz CC.

Breast Cancer Res Treat. 2011 Sep;129(2):607-16. doi: 10.1007/s10549-011-1564-5. Epub 2011 May 20.

30.

PIK3CA mutations associated with gene signature of low mTORC1 signaling and better outcomes in estrogen receptor-positive breast cancer.

Loi S, Haibe-Kains B, Majjaj S, Lallemand F, Durbecq V, Larsimont D, Gonzalez-Angulo AM, Pusztai L, Symmans WF, Bardelli A, Ellis P, Tutt AN, Gillett CE, Hennessy BT, Mills GB, Phillips WA, Piccart MJ, Speed TP, McArthur GA, Sotiriou C.

Proc Natl Acad Sci U S A. 2010 Jun 1;107(22):10208-13. doi: 10.1073/pnas.0907011107. Epub 2010 May 17.

31.

Platinum sensitivity in a BRCA1 mutation carrier with advanced breast cancer.

Rhiem K, Wappenschmidt B, Bosse K, Köppler H, Tutt AN, Schmutzler RK.

Clin Oncol (R Coll Radiol). 2009 Aug;21(6):448-50. doi: 10.1016/j.clon.2009.01.006. Epub 2009 Feb 26.

PMID:
19249193
32.

A synthetic lethal siRNA screen identifying genes mediating sensitivity to a PARP inhibitor.

Turner NC, Lord CJ, Iorns E, Brough R, Swift S, Elliott R, Rayter S, Tutt AN, Ashworth A.

EMBO J. 2008 May 7;27(9):1368-77. doi: 10.1038/emboj.2008.61. Epub 2008 Apr 3.

33.

Identification of CDK10 as an important determinant of resistance to endocrine therapy for breast cancer.

Iorns E, Turner NC, Elliott R, Syed N, Garrone O, Gasco M, Tutt AN, Crook T, Lord CJ, Ashworth A.

Cancer Cell. 2008 Feb;13(2):91-104. doi: 10.1016/j.ccr.2008.01.001.

34.

Triple negative tumours: a critical review.

Reis-Filho JS, Tutt AN.

Histopathology. 2008 Jan;52(1):108-18. doi: 10.1111/j.1365-2559.2007.02889.x. Review.

PMID:
18171422
35.

BRCA1 dysfunction in sporadic basal-like breast cancer.

Turner NC, Reis-Filho JS, Russell AM, Springall RJ, Ryder K, Steele D, Savage K, Gillett CE, Schmitt FC, Ashworth A, Tutt AN.

Oncogene. 2007 Mar 29;26(14):2126-32. Epub 2006 Oct 2.

PMID:
17016441
36.

Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition.

McCabe N, Turner NC, Lord CJ, Kluzek K, Bialkowska A, Swift S, Giavara S, O'Connor MJ, Tutt AN, Zdzienicka MZ, Smith GC, Ashworth A.

Cancer Res. 2006 Aug 15;66(16):8109-15.

37.

Exploiting the DNA repair defect in BRCA mutant cells in the design of new therapeutic strategies for cancer.

Tutt AN, Lord CJ, McCabe N, Farmer H, Turner N, Martin NM, Jackson SP, Smith GC, Ashworth A.

Cold Spring Harb Symp Quant Biol. 2005;70:139-48.

PMID:
16869747
38.

BRCA2-deficient CAPAN-1 cells are extremely sensitive to the inhibition of Poly (ADP-Ribose) polymerase: an issue of potency.

McCabe N, Lord CJ, Tutt AN, Martin NM, Smith GC, Ashworth A.

Cancer Biol Ther. 2005 Sep;4(9):934-6. Epub 2005 Sep 1.

PMID:
16251802
39.

Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy.

Farmer H, McCabe N, Lord CJ, Tutt AN, Johnson DA, Richardson TB, Santarosa M, Dillon KJ, Hickson I, Knights C, Martin NM, Jackson SP, Smith GC, Ashworth A.

Nature. 2005 Apr 14;434(7035):917-21.

40.

DSS1 is required for RAD51 focus formation and genomic stability in mammalian cells.

Gudmundsdottir K, Lord CJ, Witt E, Tutt AN, Ashworth A.

EMBO Rep. 2004 Oct;5(10):989-93. Epub 2004 Sep 10.

41.

The role of positron emission tomography in the management of colorectal cancer.

Tutt AN, Plunkett TA, Barrington SF, Leslie MD.

Colorectal Dis. 2004 Jan;6(1):2-9. Review.

PMID:
14692944
42.

Disruption of Brca2 increases the spontaneous mutation rate in vivo: synergism with ionizing radiation.

Tutt AN, van Oostrom CT, Ross GM, van Steeg H, Ashworth A.

EMBO Rep. 2002 Mar;3(3):255-60. Epub 2002 Feb 15.

43.

Supplemental Content

Support Center